Navigation Links
Applying 'supply and demand' business principles to treat infectious diseases worldwide
Date:11/17/2008

Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases. While this may sound simple, ensuring a sufficient supply of effective drugs to each country that needs them remains a challenge until the demand for those drugs is accurately predicted and understood. A new and improved scientific method to forecast the demand for a key anti-malarial treatment may be the key for how science and economics can and should intersect to maintain low-cost, high-quality drugs to combat infectious diseases. According to Justin Cohen, M.P.H., Ph.D., such a forecast is crucial in order to supply enough medications to meet demand -- especially since demand has the potential to rise very rapidly as old drugs lose effectiveness and governments switch to new drugs.

Dr. Cohen and his team from the Clinton Foundation started looking for patterns in how funding for drugs is disbursed around the world and used those patterns to forecast how future funding will look. The team used a similar approach to forecasting the demand for HIV/AIDS treatments in Africa. It worked so well that the team decided to set its sights on the treatment of malaria, which now affects 300-500 million people per year 1 million of whom die from the disease. The cost to Africa's economy alone is estimated to be $12 billion per year.

The quantitative method centers on the acquisition of a chief anti-malarial ingredient, artemisinin, which comes from plants and is used in malaria treatments. One of the challenges with artemisinin-based combination therapy (ACT) is it can take up to two years for the plants to grow, extract the artemisinin and then for pharmaceutical companies to develop the drugs. If demand isn't accurately predicted, it can lead to a shortage of drugs, driving up the cost for countries to buy them. Convers
'/>"/>

Contact: Michael Ettlemyer
mettlemyer@environics-usa.com
203-325-8772 x14
American Society of Tropical Medicine and Hygiene
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Applying Parallel Pressure Improves Vascular Grafting
2. Tumors grow faster without blood-supply promoting molecule
3. Honeywell Signs Supply Agreement with Chinese Company for Aclar(R) Film
4. BioLife Solutions to Supply CryoStor(TM) to Cryobanks International as Standard Media for Preservation and Storage of Umbilical Cord Blood Stem Cells
5. For Some Doctors, Empathy Is in Short Supply
6. Hurricane Devastation Touches the Nations Blood Supply
7. American Red Cross Issues Local Blood Supply Alert
8. University Physicians Healthcare (UPH) Selects Broadlane to Provide Comprehensive Supply Chain Services
9. Reid Supply Introduces Lifetime Warranty on New Line of Hand Tools
10. ORSupply.com Introduces New Line of Products from Flexicare
11. IDE Technologies Signs Contract Worth Over 100 Million Euros to Supply a Desalination Plant to Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... According to the the Stevens Johnson Syndrome Foundation, Stevens ... a severe allergic reaction usually to medicine (i). The ... quickly advance causing blistering and large areas of dead skin. ... can develop at any time and seriously affect both children ... Bol, passed away after he received kidney medicine which caused ...
(Date:5/18/2013)... 2013 The product liability attorneys at Wright ... behalf of consumers nationwide who have sustained serious tendon injuries ... These cases are all part of MDL 2308 and were ... will be heard in the U.S. District Court of ... & Schulte, LLC specializes in defending the rights of those ...
(Date:5/17/2013)... 17, 2013 Daily Gossip announced on Monday ... creator of the Program Yourself Thin regime, Jim ... online website by the end of the month in order ... successfully reeducate themselves and lead a healthy lifestyle, free of ... Thin package is available for only $97 and it ...
(Date:5/17/2013)... 17, 2013 Degenerative changes to the area ... felt with compression, known as the nucleus pulposus, has been ... a new study led by researchers at the Icahn School ... the journal PLOS ONE, reinforces the importance of diabetes in ... it is the first study to demonstrate that these changes ...
(Date:5/17/2013)... York, New York (PRWEB) May 17, 2013 ... firm dedicated to protecting the rights of victims injured ... (J&J)’s DePuy Orthopaedics Inc. has said in a May ... selling some of its metal-on-metal and ceramic-on-metal hip replacement ... Articulation and the Complete Ceramic-on-Metal Acetabular Hip System will ...
Breaking Medicine News(10 mins):Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:Program Yourself Thin Review and Secrets Revealed By Daily Gossip Magazine 2Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 2Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 3Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 4Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3
... TAMPA, Fla., Nov. 2 Romark Laboratories, ... phase II clinical trial showing that 79% of ... nitazoxanide plus,the standard of care had a sustained ... weeks following treatment, compared to 43%,of patients receiving ...
... Kensey Nash Corporation,(Nasdaq: KNSY ) today ... Optical Coherence Domain Reflectometry Guidewire, from Lawrence,Livermore National ... related to its chronic total occlusion (CTO) platform.,The ... capabilities,allowing it to sense locations, thickness, and structure ...
... Amedisys, Inc.,(Nasdaq: AMED or the "Company"), one of America,s ... Graham, President and,Chief Operating Officer, and Dale E. Redman, ... Markets 18th Annual Healthcare Conference in,New York on Tuesday, ... 9:10 a.m. Eastern time. The audio,presentation will be webcast ...
... Nov. 2 NxStage Medical, Inc.,(Nasdaq: NXTM ), ... machine, today announced its financial results for the,third quarter ... quarter of 2007 were $11.6 million, compared to,$5.5 million ... 111%. Revenues in,the chronic home dialysis market were $8.3 ...
... 2 Vista Partners announced,today that it has ... RPTP). "We believe Raptor,s operational approach will serve,as ... as it promotes,operational efficiency, reduced operating costs and ... a Phase II candidate for 2008 in,Convivia(TM), which ...
... (Nasdaq: KOSN ) will announce its third ... after market close. The announcement of Kosan,s ... a conference call and live webcast on November ... Eastern. Interested parties may access the,live call by ...
Cached Medicine News:Health News:Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C 2Health News:Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C 3Health News:Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C 4Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:Amedisys to Present at 2007 CIBC Healthcare Conference in New York 2Health News:NxStage Medical Reports Third Quarter 2007 Results 2Health News:NxStage Medical Reports Third Quarter 2007 Results 3Health News:NxStage Medical Reports Third Quarter 2007 Results 4Health News:NxStage Medical Reports Third Quarter 2007 Results 5Health News:NxStage Medical Reports Third Quarter 2007 Results 6Health News:NxStage Medical Reports Third Quarter 2007 Results 7Health News:NxStage Medical Reports Third Quarter 2007 Results 8Health News:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. 2Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... systems, announced today that the United States Food and ... Drug application(IND) for ORMD-0801, its oral insulin capsule. ... clearance to proceed," stated Nadav Kidron ... major milestone for Oramed and we look forward to ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Technology and Research (A*STAR) and Switzerland,s ... has been dosed in a Phase 1 clinical trial with ... Qbeta virus-like particle (VLP) technology. In this first Phase 1 ... candidate and its potential to protect against H1N1 influenza infection ...
(Date:5/16/2013)... Therapeutics, (Nasdaq: NKTR ) President and Chief Executive ... to present at the upcoming 2013 UBS Global Healthcare Conference ... New York Hotel on Tuesday, May 21, 2013 at 10:00 ... via a Webcast through a link posted in the Investor ... . This Webcast will be available for replay until June ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... Inc. (NYSE: WLP ) announced today that ... the Centers for Medicare & Medicaid Services (CMS) to ... (DME MAC) for Jurisdiction B, which includes the states ... National Government Services was originally awarded ...
... Inc. (OTC Bulletin Board: AEMD ), ... address infectious disease and cancer, disclosed today that ... Hemopurifier® within U.S. Government programs that support the ... threats. The Aethlon Hemopurifier® is the first medical ...
Cached Medicine Technology:WellPoint Subsidiary Wins Durable Medical Equipment Medicare Administrative Contract Valued at $86.7 Million 2Aethlon Medical Reestablishes Biodefense Programs 2Aethlon Medical Reestablishes Biodefense Programs 3Aethlon Medical Reestablishes Biodefense Programs 4Aethlon Medical Reestablishes Biodefense Programs 5Aethlon Medical Reestablishes Biodefense Programs 6
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Inquire...
Thermometer for Round Water Bath...
... The F340 is a basic laboratory system ... pH results can be obtained when used ... 3-in-1 electrode. • Fast and easy one ... recognition for five buffers (pH 1.68, 4.00, ...
Medicine Products: